Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Insights, Forecast to 2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Group A and Group C Meningococcal Polysaccharide Vaccine Market Insights, Forecast to 2034
After vaccination, the body can produce a humoral immune response. It is used to prevent infectious diseases caused by group A and group C meningococci, such as cerebrospinal meningitis and pneumonia.
Global Group A and Group C Meningococcal Polysaccharide Vaccine market is expected to reach to US$ 302 million in 2023, with a positive growth of %, compared with US$ 285 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Group A and Group C Meningococcal Polysaccharide Vaccine industry is evaluated to reach US$ 425.5 million in 2034. The CAGR will be 5.9% during 2023 to 2034.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
Report Covers
This report presents an overview of global Group A and Group C Meningococcal Polysaccharide Vaccine market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Group A and Group C Meningococcal Polysaccharide Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio
Segment by Type
Class 1 Vaccine
Class II Vaccine
Hospital
Clinic
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Group A and Group C Meningococcal Polysaccharide Vaccine plant distribution, commercial date of Group A and Group C Meningococcal Polysaccharide Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Group A and Group C Meningococcal Polysaccharide Vaccine introduction, etc. Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Group A and Group C Meningococcal Polysaccharide Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Global Group A and Group C Meningococcal Polysaccharide Vaccine market is expected to reach to US$ 302 million in 2023, with a positive growth of %, compared with US$ 285 million in 2024 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Group A and Group C Meningococcal Polysaccharide Vaccine industry is evaluated to reach US$ 425.5 million in 2034. The CAGR will be 5.9% during 2023 to 2034.
Meningococcal disease, caused by Neisseria meningitidis, can cause serious illness and even death. The global burden of meningococcal disease, especially serogroups A and C, drives the need for effective vaccines to prevent these infections.
Report Covers
This report presents an overview of global Group A and Group C Meningococcal Polysaccharide Vaccine market from 2018 to 2034, aiming to help readers to get a comprehensive understanding of global Group A and Group C Meningococcal Polysaccharide Vaccine market with multiple angles. Items like regional sales, revenue from 2018 to 2034 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2023 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2034 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Walvax
Lanzhou Institute of Biological Products
AIM Bio
Sanofi Pasteur
GSK
Hualan Bio
ZFSW
Changsheng
Kanghua Bio
Segment by Type
Class 1 Vaccine
Class II Vaccine
Segment by Application
Hospital
Clinic
Segment by Region
US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries
Chapter Outline
Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2034
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Group A and Group C Meningococcal Polysaccharide Vaccine plant distribution, commercial date of Group A and Group C Meningococcal Polysaccharide Vaccine, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2034 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2034 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2034 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2034
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2034 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2034
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2034 in China. Product sales and revenue analysis of China from 2018 to 2034
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2034 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2034
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2034 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2034.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Group A and Group C Meningococcal Polysaccharide Vaccine introduction, etc. Group A and Group C Meningococcal Polysaccharide Vaccine Sales, Revenue, Price and Gross Margin of each company from 2018 to 2023
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports’s Conclusions of Group A and Group C Meningococcal Polysaccharide Vaccine
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices